Buying pressure lifts GSK stock higher in today's trading

Traders Union
All News
Financial News
GSK plc rises 2.34% to GBX1969.50

Highlights

GSK repurchased 1,085,894 ordinary shares between June 15–19, 2026, as part of its ongoing buyback program, acquiring them at an average price of GBX1,950.59 each.
Treasury shares now represent 6.67% of total voting rights, with GSK holding 269,826,411 shares in treasury out of 4,046,440,349 issued.
Technicals show bullish momentum with price near recent highs, but oscillators are mixed, and GSK is expected to trade between GBX1,933 and GBX2,005 over the next week.

Treasury build alters voting rights as repurchase pace accelerates

GSK plc continued its share buyback programme, acquiring 1,085,894 ordinary shares between June 15 and June 19, 2026, at an average price of approximately 1,950.59 pence per share. These shares are added to treasury, bringing total repurchases since May 11, 2026, to 8,448,125. After these transactions, GSK holds 269,826,411 shares in treasury and has 4,046,440,349 ordinary shares in issue, which is also the number of voting rights for UK disclosure thresholds. The company reports that 6.67% of voting rights are attributable to treasury shares under UK transparency rules.

Anton Kharitonov, expert at Traders Union, views GSK's recent buyback as supportive but warns that underlying price momentum is losing steam. He notes the stock overcame technical levels but sees mixed signals from oscillators and negative Bull/Bear Power, raising doubts about sustained upside. Kharitonov is also concerned that a high proportion of treasury shares could mask genuine demand. He points out the strong volatility and divergence between price and indicators as caution flags. "Despite headline strength, I see fragile foundations — tactical traders should beware of a quick reversal if GBX1,933 fails to hold."

Viktoras Karapetjanc, expert at Traders Union, sees GSK's strategic buyback as a vote of confidence and believes the bullish structure remains intact. He highlights robust technical alignment above all moving averages and expects the market to offer further upside opportunities if resistance at GBX1,978 is breached. Karapetjanc points to the positive market response to treasury repurchases as a constructive signal for long-term investors. "Further growth is likely, and current levels present attractive setups for momentum traders as buyback activity continues to support the trend."

Bullish trend persists as price nears resistance amid mixed momentum

GSK is trading above all major daily moving averages, with the price at GBX1,969 well above the 20-day (GBX1,918), 50-day (GBX1,955), and 200-day (GBX1,870) levels. This setup signals bullish momentum in the short, medium, and long term, supported by a bullish 50-day versus 200-day alignment. Immediate focus is on resistance at GBX1,978, the week high, and support at GBX1,965, the day's high. Momentum signals are mixed, with MACD showing a buy, ADX neutral, and both RSI and Stochastic RSI around mid-range, indicating neither overbought nor oversold conditions. CCI is neutral, but Bull/Bear Power at -2.56 suggests sellers dominate intraday and signals an oversold state. The stock gained 45 points in the latest session, starting with a slight downside gap before rallying near the day's high with notable volatility at 2.58%. This indicates strength near session highs, though a divergence exists between price action and more cautious momentum oscillators.

Earlier, analysts noted that GSK was under persistent downward pressure despite share buybacks, with technical signals suggesting limited prospects for a near-term rebound. The current shift to a bullish momentum profile and recent price leadership above key averages signals potential for further strength, making sustained closes above the GBX1,978 resistance level a critical trigger for any near-term breakout.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.